

# STOCK RECOMMENDATION - MAY 23RD, 2022

#### **MARKET REVIEW**

#### For the week ended May 20th, 2022.

- The Nigerian equities market closed on a negative note last week as the All-Share Index declined by 0.23%WoW to settle at 52,979.96pts, reversing the positive momentum witnessed in the past four-consecutive weeks.
- The Year-to-Date return thus worsened to 24.03%. We note that the decline was due to sell offs on notable low-cap stocks across sectors and MTNN (-4.82%) during the week. Across sectoral indices, only the NGXINS (+3.63%) and NGXOILGS (+0.30%) closed positive while NGXBNK (-1.24%), NGXCNSMRGDS (-1.01%) and NGXINDTSR (-0.61%) all closed negative.
- TRANSCOHOT (+20.70% WoW) emerged the week's top gainer, while ROYALEX (-25.49% WoW) led the losers' chart.
  JAIZBANK and MTNN were the most traded stocks by volume and value, respectively.

# MARKET PREVIEW

#### For the week commencing May 23rd, 2022.

- In our opinion, the bond auction held last week caused a tighter system liquidity and contributed to the profit taking activities witnessed on the local bourse.
- Thus, with an upcoming Treasury Bills auction to be held during the week, we expect further profit taking on tickers that have recorded decent price appreciation in recent weeks.
- We do not rule out bargain hunting on stocks that present significant upside potential to investors. However, we expect that profit taking activities will dictate market direction.
- Hence, we expect the market to close in the negative region this week.

### THE WEEK THAT WAS (A REVIEW)

NGXASI   52,979.96   53     Market Cap [NGN'tr]   28.56   32     Market Cap [USD 'bn]   68.49   4     Volume Traded [bn]   2.24   4     NSEASI & Sectoral Indices [Return Profile]     NSEASI & Sectoral Indices [Return Profile]     NGXASI   -0.23%   6.73%   12.81%     NGX-30   -1.47%   7.64%   13.36%     NGX-B10   -1.24%   -0.94%   5.24%     NGX-FB10   -1.01%   11.87%   24.78%	7. Week 100.21 28.63 68.65
Market Cap [NGN'tr]   28.56     Market Cap [USD 'bn]   68.49     Volume Traded [bn]   2.24     Value Traded [NGN'bn]   NSEASI & Sectoral Indices [Return Profile]     NSEASI & Sectoral Indices [Return Profile]     NGX-SI   -0.23%   6.73%   12.81%     NGX-30   -1.47%   7.64%   13.36%     NGX-B10   -1.24%   -0.94%   5.24%     NGX-FB10   -1.01%   11.87%   24.78%     NGX-OG5   0.30%   6.09%   26.30%	28.63 68.65
Volume Traded [bn]     2.24       Value Traded [NGN'bn]     28.81       NSEASI & Sectoral Indices [Return Profile]       WtD     MtD     QtD       NGXASI     -0.23%     6.73%     12.81%       NGX-30     -1.47%     7.64%     13.36%       NGX-B10     -1.24%     -0.94%     5.24%       NGX-FB10     -1.01%     11.87%     24.78%       NGX-OG5     0.30%     6.09%     26.30%	
Volume Traded [bn]     2.24       Value Traded [NGN'bn]     28.81       NSEASI & Sectoral Indices [Return Profile]       WtD     MtD     QtD       NGXASI     -0.23%     6.73%     12.81%       NGX-30     -1.47%     7.64%     13.36%       NGX-B10     -1.24%     -0.94%     5.24%       NGX-FB10     -1.01%     11.87%     24.78%       NGX-OG5     0.30%     6.09%     26.30%	
Value Traded [NGN'bn]     28.81       NSEASI & Sectoral Indices [Return Profile]       WtD     MtD     QtD       NGXASI     -0.23%     6.73%     12.81%       NGX-30     -1.47%     7.64%     13.36%       NGX-B10     -1.24%     -0.94%     5.24%       NGX-FB10     -1.01%     11.87%     24.78%       NGX-OG5     0.30%     6.09%     26.30%	1.79
WtD     MtD     QtD       NGXASI     -0.23%     6.73%     12.81%       NGX-30     -1.47%     7.64%     13.36%       NGX-B10     -1.24%     -0.94%     5.24%       NGX-FB10     -1.01%     11.87%     24.78%       NGX-OG5     0.30%     6.09%     26.30%	27.17
NGXASI   -0.23%   6.73%   12.81%     NGX-30   -1.47%   7.64%   13.36%     NGX-B10   -1.24%   -0.94%   5.24%     NGX-FB10   -1.01%   11.87%   24.78%     NGX-OG5   0.30%   6.09%   26.30%	
NGX-30   -1.47%   7.64%   13.36%     NGX-B10   -1.24%   -0.94%   5.24%     NGX-FB10   -1.01%   11.87%   24.78%     NGX-OG5   0.30%   6.09%   26.30%	YtD
NGX-B10   -1.24%   -0.94%   5.24%     NGX-FB10   -1.01%   11.87%   24.78%     NGX-OG5   0.30%   6.09%   26.30%	24.03%
NGX-FB10   -1.01%   11.87%   24.78%     NGX-OG5   0.30%   6.09%   26.30%	17.89%
<b>NGX-OG5</b> 0.30% 6.09% 26.30%	6.07%
	L7.34%
NGX-INS10 3.63% -0.37% 3.32%	51.24%
	-2.91%
<b>NGX-IND</b> -0.61% 4.98% 8.39%	L4.23%
Value (NGN) Volume	
MTNN 8,053,188,566 <b>JAIZBANK</b> 526,9	13,438
GTCO 3,489,540,963 TRANSCORP 339,1	21,875
<b>SEPLAT</b> 2,847,743,733 <b>FBNH</b> 192,2	41,836
<b>FBNH</b> 2,364,024,497 <b>GTCO</b> 145,8	54,176
<b>AIRTELAFRI</b> 1,298,590,403 <b>CHIPLC</b> 101,3	08,303
Highest Gainers % Highest Losers	%
TRANSCOHOT 20.70% ROYALEX -	25.49%
NNFM 20.60% ACADEMY -	L8.54%
ABBEYBDS 20.44% FTNCOCOA -	L5.79%
PZ 12.07% MAYBAKER -	
CADBURY 11.32% GLAXOSMITH -	L4.65%



	1																		
		Funda	amentals				Trailing			Ma	rket Perforr	mance	Valuation						
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2022 TP	Last Wk. Pr	UPP	RT	
Financial Services																			
Banks																			
ACCESSCORP	0.09	19%	15%	1%	11.02	4.64	30.84	2.12x	0.32x	10.40	9.55	+5.91%	2.21	5.43	11.99	9.85	+22%	BUY	
ETI	0.09	16%	17%	1%	12.78	6.27	35.83	1.91x	0.33x	13.10	8.60	+37.36%	2.21	6.60	14.56	11.95	+22%	BUY	
FCMB	0.09	9%	9%	1%	9.96	1.14	12.57	3.08x	0.28x	3.88	2.85	+17.06%	3.15	1.38	4.35	3.50	+24%	BUY	
FIDELITYBK	0.08	13%	12%	1%	11.53	1.23	10.65	2.85x	0.33x	4.05	2.50	+36.86%	2.45	1.47	3.60	3.49	+3%	HOLD	
FBNH	0.07	10%	8%	1%	11.29	1.74	20.99	6.91x	0.57x	12.40	11.00	+5.26%	4.34	2.68	11.63	12.00	-3%	HOLD	
GTCO	0.08	36%	19%	3%	6.05	5.86	30.88	4.04x	0.77x	28.00	21.50	-8.85%	4.29	7.80	33.51	23.70	+41%	BUY	
STANBIC	0.07	22%	15%	2%	7.83	5.47	35.64	6.31x	0.97x	38.00	32.15	-4.17%	8.15	5.21	42.45	34.50	+23%	BUY	
STERLNBANK	0.09	8%	9%	1%	10.96	0.49	5.27	3.19x	0.30x	1.73	1.40	+3.31%	-	-	-	1.56	-	UR	
UBA	0.08	23%	15%	1%	10.76	3.57	24.15	2.21x	0.33x	8.85	7.50	-1.86%	2.36	3.87	9.15	7.90	+16%	BUY	
UBN	0.07	14%	6%	1%	9.58	0.56	9.23	11.63x	0.70x	6.55	5.40	+10.17%	7.16	0.96	6.90	6.50	+6%	HOLD	
WEMABANK	0.08	9%	14%	1%	17.33	0.27	1.89	12.72x	1.83x	3.85	0.78	+380.56%	-	-	-	3.46	-	UR	
ZENITHBANK	0.08	30%	19%	2%	7.76	7.95	42.37	3.03x	0.57x	27.40	22.00	-4.17%	3.71	7.98	29.59	24.10	+23%	BUY	
Insurance																			
AIICO	0.33	23%	21%	4%	5.80	0.39	1.86	1.99x	0.42x	0.84	0.64	+11.43%	5.32	0.14	0.74	0.78	-5%	HOLD	
LASACO	0.50	1%	1%	0%	2.18	0.05	6.01	20.31x	0.18x	1.15	1.00	+5.71%	5.69	0.25	1.42	1.11	+28%	BUY	
MANSARD	0.55	21%	12%	4%	3.03	0.23	1.91	9.95x	1.18x	2.60	2.15	-2.59%	6.05	0.46	2.77	2.26	+23%	BUY	
NEM	0.73	12%	20%	12%	1.72	0.49	2.43	9.01x	1.80x	4.50	3.01	-2.44%	4.96	0.96	4.76	4.39	+8%	HOLD	
WAPIC	0.41	11%	-5%	-3%	1.80	-0.04	0.94	-10.24x	0.48x	0.53	0.40	-19.64%	-		-	0.45	-	UR	
CORNERST	0.37	1%	14%	6%	2.40	0.16	1.13	3.56x	0.51x	0.74	0.50	+26.09%	3.20	0.21	0.67	0.58	+16%	BUY	
CUSTODIAN	0.43	9%	17%	5%	3.19	1.88	11.27	3.73x	0.62x	8.00	6.50	-11.39%	4.21	1.87	7.87	7.00	+12%	BUY	

\*TP calculated with EV/EBITDA multiple; TP=Target Price, Last Wk. Pr= Last Week Price, CP= Current Price, UPP=Upside Potential, RT= Rating, Exp. EPS= 2021 Dec Expected EPS, BVP= Book Value Per Share, P/E=P/E, AT=Asset Turnover, OM=Operating Margin, NM= Net Margin, Lev=Leverage, UR=Under Review. Data in the Fundamental columns are based on trailing performance.



	Fundamentals						Trai	ling		Ma	ance	Valuation						
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2022 TP	Last Wk. Pr	UPP	RT
Other Financial Services																		
UCAP	0.04	55%	50%	3%	19.45	1.99	3.98	6.85x	3.42x	14.15	9.95	+37.37%	5.50	2.33	12.82	13.60	-6%	HOLD
Consumer Staples & Discretionary																		
Breweries																		
GUINNESS	0.81	13%	6%	3%	2.30	2.54	41.12	38.64x	2.38x	110.00	39.00	+151.28%	-	-	-	98.00	-	UR
NB	0.90	10%	10%	4%	2.80	2.33	23.26	33.06x	3.31x	77.00	40.00	+54.00%	25.45	3.12	79.51	77.00	+3%	HOLD
INTBREW	0.43	1%	-10%	-3%	3.29	-0.53	5.23	-15.34x	1.57x	9.75	4.40	+65.66%	-	-	-	8.20	-	UR
Packaged Foods & Meats																		
BUAFOODS	0.57	25%	33%	12%	2.77	68.55	208.94	0.84x	0.28x	66.00	40.00	+44.75%	14.18	4.74	67.23	57.90	+16%	BUY
CADBURY	0.94	12%	255%	5%	52.50	1.28	0.50	13.85x	35.37x	17.70	7.75	+101.14%	21.58	0.34	7.34	17.70	-59%	SELL
DANGSUGAR	0.84	9%	18%	6%	2.79	1.86	10.59	9.13x	1.61x	18.30	15.50	-2.30%	8.10	2.95	23.90	17.00	+41%	BUY
HONYFLOUR	0.90	0%	2%	1%	2.45	0.13	7.26	29.27x	0.52x	4.02	3.20	+10.29%	23.17	0.13	3.01	3.75	-20%	SELL
FLOURMILL	1.48	2%	15%	4%	3.80	6.63	45.11	5.58x	0.82x	41.45	28.10	+30.51%	6.48	6.27	40.63	37.00	+10%	HOLD
NASCON	0.80	4%	-11%	-4%	2.96	-0.60	5.67	-21.54x	2.27x	14.50	11.70	-2.65%	12.54	1.26	15.80	12.85	+23%	BUY
NESTLE	1.16	16%	116%	14%	8.26	57.54	49.54	24.35x	28.29x	1,556.50	1,395.00	-9.96%	28.18	54.57	1,537.78	1,401.40	+10%	HOLD
UACN	0.93	2%	5%	2%	2.24	0.89	17.87	16.21x	0.81x	14.50	8.90	+51.58%	12.48	1.21	15.16	14.40	+5%	HOLD
UNILEVER*	0.64	9%	-2%	-1%	1.72	-0.18	11.76	-81.84x	1.26x	15.30	12.20	+2.07%	27.13	0.56	15.07	14.80	+2%	HOLD
Agricultural Products																		
ОКОМИОІЬ	0.56	46%	36%	19%	1.86	16.53	45.65	13.01x	4.71x	215.00	127.80	+51.41%	10.11	15.63	158.02	215.00	-27%	SELL
PRESCO	0.38	40%	26%	15%	1.67	18.87	73.77	10.60x	2.71x	200.00	87.80	+127.79%	8.25	26.25	216.54	200.00	+8%	HOLD
Household & Personal Products						-												
PZ	0.79	1%	-20%	-8%	2.55	-1.71	8.76	-7.59x	1.48x	13.55	6.10	+113.11%	-	-	-	13.00	-	UR
VITAFOAM	0.92	19%	44%	18%	2.46	4.57	10.35	5.19x	2.29x	25.00	20.25	+5.33%	6.00	4.90	29.40	23.70	+24%	BUY

# **Equity | Stock Recommendation**

	Eundamentale						Trailing				ormance		Valuation						
	Fundamentals																		
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	EPS	2022 TP	Pr	UPP	RT	
Healthcare																			
Pharmaceuticals																			
MAYBAKER	0.70	6%	13%	6%	2.38	0.57	4.32	7.53x	1.00x	5.45	4.02	+7.21%	7.50	0.67	5.03	4.31	+17%	BUY	
FIDSON	0.95	14%	31%	13%	2.44	2.20	7.13	5.01x	1.54x	12.05	6.22	+76.85%	5.03	2.06	10.35	11.00	-6%	HOLD	
GLAXOSMITH	0.99	3%	11%	4%	2.79	0.91	7.91	7.65x	0.88x	8.35	5.65	+16.81%	-	-	-	6.95	-	UR	
NEIMETH	0.47	13%	15%	3%	5.89	0.08	0.56	20.88x	3.13x	1.98	1.36	+0.57%	2.55	0.86	2.19	1.76	+25%	BUY	
Materials									•										
Construction Materials																	•		
BUACEMENT*	0.37	34%	23%	13%	1.82	2.98	12.73	24.93x	5.83x	74.25	68.00	+10.74%	18.34	3.19	76.13	74.25	+3%	HOLD	
DANGCEM*	0.60	38%	37%	16%	2.33	22.93	61.93	13.08x	4.84x	300.00	250.00	+16.73%	6.90	44.81	287.81	300.00	-4%	HOLD	
WAPCO*	0.58	19%	15%	11%	1.35	3.69	24.59	7.81x	1.17x	31.75	21.80	+20.25%	6.46	38.65	38.65	28.80	+34%	BUY	
Specialty Chemicals															-				
САР	1.36	11%	31%	13%	2.50	1.99	6.33	10.56x	3.32x	22.40	17.55	+7.97%	12.38	1.32	16.34	21.00	-22%	SELL	
BERGER	1.06	5%	6%	4%	1.54	0.66	11.46	11.44x	0.65x	8.55	6.15	-12.28%	12.00	0.74	8.92	7.50	+19%	BUY	
Energy																			
CONOIL	2.17	2%	14%	6%	2.47	4.63	32.20	6.72x	0.97x	31.50	21.30	+41.59%	7.81	4.05	31.58	31.15	+1%	HOLD	
ETERNA	1.93	3%	-4%	-1%	3.78	-0.37	9.97	-19.41x	0.71x	7.31	4.99	+40.59%	-	_	5.79	7.10	-18%	SELL	
ARDOVA	2.93	-1%	-9%	-3%	3.60	-1.27	13.86	-11.83x	1.08x	15.20	11.55	+15.38%	8.21	2.08	17.08	15.00	+14%	BUY	
MRS	2.02	0%	2%	1%	2.10	0.96	56.24	14.12x	0.24x	13.60	12.20	+10.12%	55.23	0.20	11.05	13.60	-19%	SELL	
SEPLAT	0.20	8%	6%	3%	2.29	77.78	1,222.95	16.71x	1.06x	1,300.10	650.00	+99.98%	13.14	86.37	1,134.94	1,299.90	-13%	SELL	
TOTAL	1.37	4%	40%	7%	5.88	53.78	135.71	4.36x	1.73x	264.90	221.90	+5.68%	5.60	53.36	298.86	234.50	+27%	BUY	
Telecommunications																			
MTNN	0.77	21%	121%	14%	8.53	15.81	13.02	15.75x	19.13x	270.00	185.50	+26.40%	13.00	18.28	237.64	249.00	-5%	HOLD	
AIRTELAFRI*	0.47	25%	30%	10%	2.95	114.89	383.44	12.79x	3.83x	1,470.00	955.00	+53.93%	4.81	180.86	869.94	1,470.00	-41%	SELL	



#### **Analyst's Certification and Disclaimer**

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

**Analysts' Compensation:** The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

#### **Investment Ratings**

#### Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

#### **Target Price Estimate**

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

#### **Ratings Specification**

**BUY:** Target Price of the stock is above the current market price by at least 10 percent

**HOLD:** Target Price of the stock ranges between **-10 percent and 10 percent** from the current market price.

SELL: Target Price of the stock is more than 10 percent below the current market price.

#### **Definitions**

**Price Targets:** Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

**Asset allocation:** The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.



#### **Conflict of Interest**

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

#### **Important Disclosure**

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Meristem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

#### Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, **the** company through its subsidiaries carries out stock broking, wealth management, trustees and registrars' businesses which are regulated by the SEC and ICMR.

#### IMPORTANT INFORMATION: DISCLAIMER

Meristem Securities Limited ('Meristem') equity reports and its attendant recommendations are prepared based on publicly available information and are meant for general information purposes only and it may not be reproduced or distributed to any other person. All reasonable care has been taken to ensure that the information contained herein is not misleading or untrue at the time of publication; Meristem can neither guarantee its accuracy nor completeness as they are an expression of our analysts' views and opinions.

Meristem and any of its associated or subsidiary companies or the employees thereof cannot be held responsible for any loss suffered by relying on the said information as this information as earlier stated, is based on publicly available information, analysts' estimates and opinions and is meant for general information purposes and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell securities or any financial instruments. The value of any investment is subject to fluctuations, i.e. may fall and rise. Past performance is no guide to the future. The rate of exchange between currencies may cause the value of investment to increase or diminish. Hence investors may not get back the full value of their original investment.

Meristem Securities is registered with the Securities and Exchange(SEC) and is also a member of The Nigerian Stock Exchange (The NSE). Meristem Securities' registered office is at 124 Norman Williams Street, South West, Ikoyi, Lagos, Nigeria. Website: www.meristemng.com; Email: research@meristemng.com. © Meristem Securities Limited 2022.



#### **EQUITY | STOCK RECOMMENDATION**

# **Contact Information**

## **Brokerage and Retail Services**

topeoludimu@meristemng.com (+234 905 569 0627) isaaconaolapo@meristemng.com (+234 803 234 8275) contact@meristemng.com

# **Investment Banking/Corporate Finance**

rasakisalawu@meristemng.com (+234 806 022 9889) seunlijofi@meristemng.com (+234 808 536 5766)

# **Wealth Management**

funmilolaadekola-daramola@meristemng.com (+234 805 498 4522)

crmwealth@meristemng.com Tel: +234 01 738 9948

## Registrars

muboolasoko@meristemregistrars.com (+234 803 324 7996) martinaosague@meristemregistrars.com (+234 802 303 1783) www.meristemregistrars.com

Tel: +23401-280 9250

#### **Trust Services**

damilolahassan@meristemng.com (+234 803 613 9123) trustees@meristemng.com

# **Group Business Development**

saheedbashir@mersitemng.com (+234 802 454 6575) ifeomaogalue@meristemng.com (+234 802 394 2967) info@meristemng.com

#### **Client Services**

adefemitaiwo@meristemng.com (+234 803 694 3034) car@meristemng.com

#### **Investment Research**

<u>damilareojo@meristemng.com</u> <u>praiseihansekhien@meristemng.com</u> research@meristemng.com

Corporate websites: www.meristemng.com www.meristemwealth.com www.meristemregistrars.com

#### Meristem Research can also be accessed on the following platforms:

Meristem Research portal: research.meristemng.com

**Bloomberg:** MERI <GO>

Capital IQ: www.capitaliq.com Reuters: www.thomsonreuters.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG FactSet: www.factset.com